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A variant of foot-and-mouth disease virus (FMDV) lacking the leader (L) coding region (A12-LLV2) was previously con-
structed and shown to be less virulent in cattle than its wild-type parent (A12-IC). In this study, cattle were tested for their
clinical and immunological responses to subcutaneous inoculation with A12-LLV2 or A12-IC or to intramuscular vaccination
with chemically inactivated A12-IC. Five weeks postinoculation animals were challenged by intradermal inoculation in the
tongue with a virulent cattle-passaged virus. A12-LLV2-inoculated animals showed no clinical signs of disease and developed
a neutralizing antibody response by 4 days postinoculation, whereas a companion control bovine did not seroconvert. After
challenge, two of three inoculated animals did not develop lesions, but showed mild signs of infection. The third inoculated
animal developed some lesions, but these were less severe than in the uninoculated control animal, which showed classical
FMD. All animals inoculated with A12-IC developed a fever, two showed typical FMD lesions, and the companion control
seroconverted, indicating that it had acquired infection by contact. The A12-IC-inoculated animals and the control were
protected from challenge. Animals vaccinated with inactivated virus showed no clinical signs of disease and developed a
neutralizing antibody response, and the control did not seroconvert. Upon challenge none of the vaccinated animals devel-
oped lesions, one developed a fever, and the control developed FMD. These experiments demonstrate the potential of a
rationally designed live-attenuated FMDV vaccine. q 1997 Academic Press
INTRODUCTION al., 1981; Beck and Strohmaier, 1987), the development
of the carrier state in some vaccinated animals following
Foot-and-mouth disease (FMD), caused by a member
contact with FMDV (Bachrach, 1968, 1978; Salt, 1993),
of the Aphthovirus genus of the family Picornaviridae, is
and the relatively short-lived immunity of vaccinated ani-
a highly contagious disease of cloven-hoofed animals
mals, have been identified (Bachrach, 1968). Various
that is spread by aerosol. The disease is characterized
workers have attempted to develop live-attenuated virus
by temporary and debilitating oral and pedal vesicles
vaccines, derived by passage in alternate hosts and/or
which can result in a significant decline in production of
in tissue culture, but it has been difficult to obtain viruses
meat or dairy products. Because of these problems and
that are both attenuated and immunogenic (Bachrach,
its highly infectious nature, trade embargos are enforced
1968; Brooksby, 1982).
against countries with FMD, making it the most economi-
Like other picornaviruses, FMDV contains a single-
cally important disease of livestock worldwide (Bachrach,
stranded, positive-sense RNA genome of approximately1978; McCauley et al., 1979). Thus, most countries which
8300 nucleotides surrounded by an icosahedral capsidare free of FMD maintain rigid quarantine and import
containing 60 copies of each of 4 structural proteins. Therestrictions to prevent its introduction, while control pro-
RNA genome contains a single, long open reading framegrams to eliminate the disease include slaughter of in-
that codes for the 4 structural proteins and a number offected and exposed animals and ring vaccination using
nonstructural proteins which function in various aspectskilled vaccine.
of the virus replication cycle. FMDV and cardiovirusesThe development of a chemically inactivated FMDV
also contain a homopolymeric poly(C) tract of unknownvaccine has led to the successful eradication of the dis-
function close to the 5* end of the genome (Brown et al.,ease from western Europe (Brown, 1992) and to its grad-
1974). For FMDV it has been suggested that the poly(C)ual elimination from other countries. Although these
tract has a role in determining virulence (Harris andkilled vaccines have been effective, recurrent problems,
Brown, 1977), but other studies cast doubt on this possi-including shortcomings in vaccine manufacture (King et
bility (Costa Giomi et al., 1988; Escarmis et al., 1992).
However, genetically engineered mengoviruses con-
1 Present address: Instituto de Biotecnologı´a, CICV-INTA, C.C. 77
taining short poly(C) tracts have been produced (Duke(1708) Moro´n, Buenos Aires, Argentina.
and Palmenberg, 1989) and shown to be dramatically2 To whom correspondence and reprint requests should be ad-
dressed. Fax: (516) 323-2507. E-mail: mgrubman@asrr.arsusda.gov. attenuated in mice, swine, and other nonhuman primates
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(Osorio et al., 1996). In contrast, we demonstrated that of FMDV type A12 (Vallee strain 119, cattle passage 78)
was used as the challenge virus (Cottral et al., 1965;genetically engineered FMDV with a poly(C) tract of 2
nucleotides is virulent in mice (Rieder et al., 1993) and McKenna et al., 1995).
likewise studies have shown that encephalomyocarditis
Bovinesviruses containing short poly(C) tracts are only slightly
attenuated, if at all, compared to wild-type virus (Hahn Twelve Hereford steers, aged 9–12 months, were used
and Palmenberg, 1995). in the study. Animals were sorted into three test groups
Our current approach toward development of a live- of four animals each and housed in separate rooms. In
attenuated FMDV is to manipulate the coding region of each group there were three inoculated animals and one
the genome. One of the viral nonstructural proteins, uninoculated control. Each group of three animals was
leader (L), is a papain-like proteinase (Gorbalenya et al., inoculated subcutaneously with either 107 PFU A12-LLV2
1991; Kleina and Grubman, 1992; Piccone et al., 1995b; or A12-IC (corresponding to approximately 1 mg of virus)
Roberts and Belsham, 1995) that autocatalytically or intramuscularly (the standard route used in the field)
cleaves itself from the polyprotein (Strebel and Beck, with 2 mg of sucrose gradient-purified BEI-inactivated
1986) and cleaves p220 (recently named eIF-4G), a sub- A12-IC (Bahnemann, 1990) emulsified in mineral oil (9:1
unit of the cap-binding protein complex eIF-4F involved Marcol 52/Montanide 888). The animals were challenged
in the initiation of translation at the 5* end of most eukary- by IDL inoculation at 35–36 days postinoculation with 104
otic mRNAs (Devaney et al., 1988; Kirchweger et al., 1994; PFU of the virulent cattle-passaged virus (approximately
Medina et al., 1993). Cleavage of p220 correlates with 20,000 cattle-infectious doses) and observed daily for
the shutoff of cap-dependent host protein synthesis clinical signs including fever and vesicular lesions.
(Etchison et al., 1982) which occurs in FMDV-infected
cells, allowing for unimpeded translation of viral RNA Serological assays
which is cap-independent.
Blood was collected at regular intervals pre- and post-We have recently constructed a genetically altered
challenge, and serum was separated, heat-inactivated atvariant of FMDV which is lacking the coding region for
567 for 30 min, stored at0707, and subsequently assayedthe L proteinase (Piccone et al., 1995a). The leaderless
for neutralizing antibodies by a plaque reduction assayvirus (A12-LLV2) replicates more slowly than wild-type
in BHK-21 cells. Neutralization titers were reported as(WT) virus in BHK-21 cells and is slightly attenuated in
the log of serum dilution yielding a 70% reduction in PFUsuckling mice (Piccone et al., 1995a). In a recent study
(PRN70). Just prior to challenge, nasal secretions werein bovines, we showed that after aerosol exposure A12-
obtained (Israel et al., 1992) and assayed for neutralizingLLV2 is less virulent relative to parental WT virus derived
antibodies by PRN70 . To determine if animals were virusfrom a full-length infectious clone (A12-IC), is less widely
carriers, esophagopharyngeal (OP) samples were col-disseminated in the lung, and does not spread systemi-
lected, homogenized, treated with freon, filtered, andcally to epithelial sites in the feet (Brown et al., 1996). The
blind-passaged on BHK-21 cells for up to 3 days. Super-greatly reduced pathogenicity of A12-LLV2 in bovines
natants were titered and if plaques were obtained a PRNidentifies it as a candidate for a modified-live viral vac-
assay was performed with serum from a bovine that hadcine.
been vaccinated with BEI-inactivated FMDV A12 to con-In the present study, we have examined the virulence
firm that the virus was FMDV.and immunogenicity of A12-LLV2 in bovines after subcu-
taneous inoculation and compared its potency and effi-
RESULTScacy to a binary ethylenimine (BEI)-inactivated virus vac-
cine following challenge by intradermal inoculation in the Experimental outline
tongue (IDL) with a virulent cattle-passaged A12 virus.
To compare the virulence of A12-IC with A12-LLV2
a preliminary experiment was performed by intradermalMATERIALS AND METHODS
inoculation of bovines at multiple sites on the tongue
Cell lines and viruses
with different amounts of each virus. As a control, a viru-
lent cattle-passaged virus was also used and the animalsBaby hamster kidney (BHK) cells (strain 21, clone 13)
were used to propagate virus stocks and were used in were monitored clinically. This route of inoculation has
been shown to be an extremely sensitive method of de-plaque assays. Parental WT FMDV A12 119 (A12-IC) was
derived from the full-length infectious clone pRMC35 (Rie- tecting the presence of FMDV (Henderson, 1952). The
animal inoculated with the cattle-derived virus developedder et al., 1993), and A12-LLV2 was derived from the
infectious clone lacking the Lb coding region pRM-LLV2 coalescing tongue lesions at the lowest dose used, 5
PFU, by 2 days postinoculation (dpi) and by 3 days le-(Piccone et al., 1995a). Fourth-passage virus stocks were
used in all experiments. A virulent cattle-passaged strain sions were present on the feet. The animal inoculated
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FIG. 1. Inoculation of bovines with A12-LLV2 and challenge with virulent virus. Three bovines, Nos. 13, 73, and 74, were inoculated subcutaneously
with 107 PFU A12-LLV2 and a fourth animal, No. 9, housed in the same room, served as a control. The animals were observed daily for clinical
signs including fever and lesions and were bled regularly, and serum and nasal secretions were tested by PRN70 . At 35 dpi the animals were
challenged by IDL inoculation with 104 PFU of cattle-passaged A12 virus and observed as above.
with A12-IC showed coalescing lesions only after 3 days tralizing antibody response by 4 dpi (PRN70 from 1.6 to
2.5) which increased at 7 dpi (PRN70 from 2.3 to 3.2)at 5 PFU. However, the A12-LLV2-inoculated animal did
and remained essentially constant until the animals werenot have any lesions even at 725,000 PFU. This experi-
challenged at 35 dpi. The control animal, No. 9, did notment showed that, in the bovine, A12-LLV2 was at least
seroconvert and showed no clinical signs of disease. At105-fold less virulent than its parent, A12-IC, which in
35 dpi nasal secretions were obtained from each animalturn was slightly less virulent than the cattle-passaged
and only the inoculated animals showed a low-level neu-virus.
tralizing antibody response (Table 1).Based on this preliminary observation, a series of ex-
The four animals were challenged, at 35 dpi, by IDLperiments was conducted to characterize the virulence
inoculation with 104 PFU of a virulent cattle-passagedof A12-LLV2 and A12-IC in greater detail and determine
A12 virus (Fig. 1). The control animal, No. 9, developedtheir potency and efficacy compared to the standard BEI-
a fever on the first day postchallenge and it remainedinactivated vaccine. Animals given A12-LLV2 or A12-IC
over 39.57 for 4 consecutive days. This animal developedwere inoculated subcutaneously, since we had pre-
lesions on all four feet. Bovine No. 73, which had theviously demonstrated that this route induced a significant
highest neutralizing antibody response, developed a fe-neutralizing antibody response in bovines (data not
ver of over 39.57 for only 1 day and did not develop anyshown). Animals were vaccinated with BEI-inactivated
pedal lesions. Bovine No. 74 developed a fever of overvirus by the approved standard intramuscular route.
39.57 for 4 days, but did not show any pedal lesions.Three animals per group were inoculated once with 107
Bovine No. 13, which had the lowest neutralizing anti-PFU A12-LLV2 or A12-IC, or 2 mg BEI-inactivated A12-IC.
body titer of the group, developed a fever for the first 3A control, noninoculated, animal was placed in the room
days after challenge, again from 7 to 13 days postchal-with each of the above groups.
lenge (dpc) and showed lesions on some of the feet, but
their appearance was delayed and less severe com-A12-LLV2-inoculated animals
pared to bovine No. 9, which developed lesions on all
None of the inoculated animals, Nos. 13, 73, and 74, four feet. No virus was detected in OP fluids collected
at 2, 4, 8, 15, and 31 dpi from these animals. OP samplesshowed clinical signs (Fig. 1), but all developed a neu-
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TABLE 1
Summary of Immune Responses to Inoculation, and Challenge
Prechallengea Postchallengeb
Vaccinec Animal No. Serum NTd Mucosal NTe Serum NTd Disease?f
None 9 0.6 0.6 4.2 //
A12-LLV2 13 2.0 0.6 4.9 /
A12-LLV2 73 2.9 0.6 4.3 0
A12-LLV2 74 2.6 0.6 4.6 {
Noneg 56 3.3 1.5 3.5 0
A12-IC 40 3.6 1.8 3.3 0
A12-IC 47 3.6 2.1 3.3 0
A12-IC 58 3.9 1.2 3.6 0
None 50 0.6 0.9 4.5 //
BEI-virus 51 3.8 3.2 4.5 0
BEI-virus 52 2.9 1.8 4.8 {
BEI-virus 55 4.1 2.9 (Died)h (Died)h
a Serum and nasal secretions collected 35 or 36 days postinoculation.
b Serum samples collected 13 –15 days postchallenge.
c A12-LLV2 and A12-IC were administered subcutaneously; BEI-inactivated virus was given intramuscularly in oil.
d Log of serum dilution giving a 70% reduction in PFU (see Materials and Methods).
e Log of mucosal secretion dilution giving a 70% reduction in PFU (see Materials and Methods).
f Disease profile: //, lesions on all four feet; /, lesions on one or more feet; {, no pedal lesions, but fever 407 for more than 3 days; 0, no
pedal lesions or fever of 407 for more than 1 day.
g Animal apparently acquired infection from jointly housed A12-IC inoculated animals.
h Animal No. 55 died Day 4 postchallenge from non-FMD causes; see text.
were collected at various times from 30 to 108 dpc and oped typical signs of FMD and seroconverted. Of the
three vaccinated animals, No. 55, which had the highestvirus was isolated from bovine No. 9 at 40 and 46 dpc,
while of the inoculated animals, only No. 73 had virus prechallenge neutralizing antibody titer, died on the third
day after challenge from non-FMD causes. Bovine No.and only at 44 dpc.
52, which had the lowest prechallenge titer, had a fever
A12-IC-inoculated animals of over 407 for 3 days and an increase in neutralizing
antibody titer, but no other signs of FMD. Bovine No. 51Animals inoculated with the parental WT virus, Nos.
was completely protected from disease, but had a slight40, 47, and 58, developed typical signs of FMD, i.e., fever
rise in neutralizing antibody titer. No virus was detectedand epithelial lesions, and all three animals had high
in OP fluids collected at 32, 34, 67, or 74 dpc.levels of neutralizing antibody (Fig. 2). The control animal,
No. 56, seroconverted by 15 dpi (PRN70 3.8), but showed
DISCUSSIONno signs of FMD. All four animals developed a relatively
high neutralizing antibody titer in their nasal secretions In this communication, we have demonstrated that a
(Table 1). Upon challenge all four animals were fully pro- genetically altered variant of FMDV, A12-LLV2, can be
tected and showed no increase in neutralizing antibody safely administered to cattle and that it induces a neu-
titer. Virus was recovered in the OP samples of the con- tralizing and protective antibody response. The inocuity
trol animal at 8 and 30 dpi and in No. 47 at 15 dpi, but was of A12-LLV2 was shown by direct inoculation into the
not recovered from any of the other samples collected up tongue, supporting our recent studies showing that aero-
to 76 dpc. sol exposure of bovines to A12-LLV2 failed to produce
disease (Brown et al., 1996). Additionally, in contrast to
BEI-A12-vaccinated animals
WT virus, A12-LLV2 did not spread from the subcutane-
ously inoculated animals to an uninoculated control.The three vaccinated animals, Nos. 51, 52, and 55,
showed no signs of disease, developed significant serum These experiments demonstrate that 107 to 108 PFU A12-
LLV2 is nonpathogenic in bovines, yet one dose of theneutralizing antibody titers as well as high neutralizing
titers in nasal secretions (Fig. 3 and Table 1). The control virus is able to induce a rapid immune response. Upon
challenge by IDL inoculation with approximately 20,000animal, No. 50, showed no signs of disease and did not
seroconvert. Upon challenge the control animal devel- cattle-infectious doses of a virulent cattle-passaged vi-
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FIG. 2. Inoculation of bovines with A12-IC and challenge with virulent virus. Three bovines, Nos. 40, 47, and 58, were inoculated subcutaneously
with 107 PFU A12-IC and a fourth animal, No. 56, housed in the same room, served as a control. The animals were observed daily for clinical signs
including fever and lesions and were bled regularly, and serum and nasal secretions were tested by PRN70 . At 36 dpi the animals were challenged
by IDL inoculation with 104 PFU of cattle-passaged A12 virus and observed as above.
rus, two of three A12-LLV2-inoculated animals were pro- 15 years, we have acquired comprehensive information
on the FMDV genome, including the identification andtected from disease (pedal vesicles) and the third animal
had a disease of reduced severity. In this study, the level partial characterization of all the viral-encoded structural
and nonstructural proteins and knowledge of their roleof protection of cattle following A12-LLV2 inoculation was
similar to the protection afforded cattle after vaccination in virus replication, as well as an understanding of the
function of noncoding regions of the viral genome. Morewith standard BEI-inactivated virus. It should be empha-
sized that the route of challenge used in this study is recently the complete nucleotide sequence of a number
of subtypes and serotypes of FMDV has been determinedsevere, since virus is directly inoculated into susceptible
tissue where it is able to multiply sufficiently to produce and infectious full-length cDNA clones of type O1 (Zibert
et al., 1990) and A12 (Rieder et al., 1993) have beena lesion. In previous studies, cattle vaccinated with a
similar BEI-inactivated virus were fully protected when constructed. This extensive knowledge of the virus at the
molecular level and the relative ease of manipulation ofchallenged by contact exposure to an infected pig (Mc-
Kenna et al., 1995). The potency test we utilized, IDL recombinant DNA allows for the rational development
of a live-attenuated viral vaccine from full-length cDNAinoculation with 20,000 cattle-infectious doses on the up-
per surface of the tongue followed by scoring transmis- clones. Based on this information, we have constructed
a genetic variant of FMDV that has a complete deletionsion as the presence of lesions on the feet, is similar to
that recommended by the Office International des Epizo- of a viral coding region. This approach, as opposed to
passage on unnatural hosts which selects point muta-oties (Donaldson and Doel, 1992).
tions, significantly reduces the risk of this virus revertingHistorically, attenuated FMDV vaccines have been pro-
to virulence.duced by passage in alternate hosts and/or in tissue
culture (Brooksby, 1982). However, it proved difficult to The leader coding region of FMDV is at the 5* end of
the long open reading frame and codes for a proteinasedevelop strains that were both attenuated and able to
induce an immunogenic response in cattle (Brooksby, that is directly involved in the shutoff of host protein
synthesis as a result of the cleavage of a translation1982). An additional problem with live-attenuated viruses
is the possibility of reversion to virulence. Over the past initiation factor required for the cap-dependent transla-
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FIG. 3. Vaccination of bovines with BEI-inactivated A12-IC and challenge with virulent virus. Three bovines, Nos. 51, 52, and 55, were inoculated
intramuscularly with 2 mg BEI-inactivated A12-IC and a fourth animal, No. 50, housed in the same room, served as a control. The animals were
observed daily for clinical signs including fever and lesions and were bled regularly, and serum and nasal secretions were tested by PRN70 . At 35
dpi the animals were challenged by IDL inoculation with 104 PFU of cattle-passaged A12 virus and observed as above. *Died day 4 postchallenge.
tion of most eukaryotic mRNAs (Devaney et al., 1988; The results of our experiments with A12-LLV2 suggest
that a leaderless virus could be used as a possible FMDMedina et al., 1993; Kirchweger et al., 1994). Deletion of
this coding region should result in a virus that replicates vaccine. Additional studies identifying the optimal regi-
men of live-attenuated virus inoculation are planned. Themore slowly than WT virus, since it has lost a portion of
its competitive advantage over cellular mRNAs. Initial possibility that intranasal inoculation, which would mimic
the natural route of infection, could induce local mucosalexperiments in tissue culture and animals support this
expectation. In BHK-21 cells, we have observed that A12- immunity as an additional barrier against virus replication
is worth examining.LLV2 replicates more slowly than WT virus in a single-
cycle growth curve, is less efficient in host cell protein
synthesis shutoff, and is delayed in the initiation of viral
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